Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Assets (2016 - 2026)

Ocular Therapeutix has reported Current Assets over the past 14 years, most recently at $706.0 million for Q1 2026.

  • For Q1 2026, Current Assets rose 82.1% year-over-year to $706.0 million; the TTM value through Mar 2026 reached $706.0 million, up 82.1%, while the annual FY2025 figure was $782.1 million, 77.36% up from the prior year.
  • Current Assets for Q1 2026 was $706.0 million at Ocular Therapeutix, down from $782.1 million in the prior quarter.
  • Over five years, Current Assets peaked at $782.1 million in Q4 2025 and troughed at $100.7 million in Q2 2023.
  • A 5-year average of $342.4 million and a median of $387.0 million in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 38.64% in 2023 and later skyrocketed 395.06% in 2024.
  • Year by year, Current Assets stood at $129.6 million in 2022, then skyrocketed by 79.16% to $232.2 million in 2023, then surged by 89.89% to $441.0 million in 2024, then skyrocketed by 77.36% to $782.1 million in 2025, then fell by 9.73% to $706.0 million in 2026.
  • Business Quant data shows Current Assets for OCUL at $706.0 million in Q1 2026, $782.1 million in Q4 2025, and $387.0 million in Q3 2025.